We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Qiagen
QGEN
$8.73B
| $5.51M | 0.01% |
153,726
+769
| +0.5% | +$28.6K |
|
1202
Cavco Industries
CVCO
$4.2B
| $5.49M | 0.01% |
28,084
+1,347
| +5% | +$264K |
|
|
VG
1203
DELISTED
Vonage Holdings Corporation
VG
| $5.46M | 0.01% |
737,312
+38,562
| +6% | +$333K |
|
1204
La-Z-Boy
LZB
$1.64B
| $5.46M | 0.01% |
173,372
+7,348
| +4% | +$246K |
|
|
BERY
1205
DELISTED
Berry Global Group, Inc.
BERY
| $5.46M | 0.01% |
125,108
+1,518
| +1% | +$60.1K |
|
|
IMMU
1206
DELISTED
Immunomedics Inc
IMMU
| $5.44M | 0.01% |
256,999
+8,876
| +4% | +$157K |
|
1207
FIVE9
FIVN
$2.22B
| $5.42M | 0.01% |
82,643
+2,964
| +4% | +$181K |
|
|
KYNB
1208
Kyntra Bio
KYNB
$27.4M
| $5.42M | 0.01% |
5,052
+214
| +4% | +$218K |
|
|
UFS
1209
DELISTED
DOMTAR CORPORATION (New)
UFS
| $5.41M | 0.01% |
141,346
-7,493
| -5% | -$277K |
|
|
CSII
1210
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.4M | 0.01% |
111,097
+5,796
| +6% | +$264K |
|
1211
HEICO Corp
HEI
$50.4B
| $5.38M | 0.01% |
47,160
+437
| +0.9% | +$53.8K |
|
|
INN
1212
Summit Hotel Properties
INN
$749M
| $5.38M | 0.01% |
436,249
+23,343
| +6% | +$280K |
|
1213
CNX Resources
CNX
$5.33B
| $5.37M | 0.01% |
607,269
-26,892
| -4% | -$210K |
|
1214
Employers Holdings
EIG
$910M
| $5.37M | 0.01% |
128,605
+5,854
| +5% | +$249K |
|
1215
Nu Skin
NUS
$251M
| $5.37M | 0.01% |
131,017
+795
| +0.6% | +$32.4K |
|
1216
BWX Technologies
BWXT
$15.9B
| $5.36M | 0.01% |
86,350
+1,176
| +1% | +$69.9K |
|
|
CTB
1217
DELISTED
Cooper Tire & Rubber Co.
CTB
| $5.34M | 0.01% |
185,884
+8,926
| +5% | +$252K |
|
|
KEM
1218
DELISTED
KEMET Corporation
KEM
| $5.34M | 0.01% |
197,500
+10,275
| +5% | +$250K |
|
|
UNIT
1219
Uniti Group
UNIT
$2.34B
| $5.33M | 0.01% |
649,847
+30,799
| +5% | +$223K |
|
|
AVNS
1220
DELISTED
Avanos Medical
AVNS
| $5.33M | 0.01% |
158,253
-5,875
| -4% | -$213K |
|
|
MDRX
1221
DELISTED
Veradigm Inc. Common Stock
MDRX
| $5.33M | 0.01% |
542,954
+1,471
| +0.3% | +$15.5K |
|
|
PDM
1222
Piedmont Realty Trust
PDM
$1.24B
| $5.32M | 0.01% |
239,177
+13,746
| +6% | +$296K |
|
1223
Methode Electronics
MEI
$499M
| $5.31M | 0.01% |
134,834
+6,798
| +5% | +$247K |
|
1224
Rithm Capital
RITM
$5.62B
| $5.28M | 0.01% |
327,881
+4,142
| +1% | +$65K |
|
|
CATM
1225
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $5.28M | 0.01% |
118,209
+4,814
| +4% | +$183K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.